Skip to main content

Field Guide · Biotech

AI Visibility for Biotech. Get cited when buyers ask AI about your platform, your portfolio, your regulatory posture.

Biotech buyers — pharma BD, CROs, hospital procurement, biotech investors — are using ChatGPT, Perplexity, Claude, and Gemini to scope partners before the first conversation. Bttr. builds AI search visibility for biotech operators, including the platform work for Tiger BioSciences (AlloClae, Bellafill, Aveli, Sientra).

New to AI Search Visibility? Start with the definitional field guide → What Is AI Search Visibility?

Why biotech is different from generic AI visibility.

Biotech buyers ask AI engines questions loaded with specific terminology: FDA pathway (510k, PMA, BLA), GxP compliance posture, GLP / GCP / GMP applicability, indication-specific data, regulatory body (FDA, EMA, MHRA), CDx companion-diagnostic relationships. The citation surface here is fundamentally taxonomy-anchored.

Authority compounds on factual accuracy and named expertise. A page that misstates a regulatory pathway, mislabels an indication, or implies off-label use gets penalized by every engine — Perplexity flags it, Gemini downranks it, Claude refuses to cite it. The same accuracy bar that protects you in FDA review protects you in AI citation.

Bttr. has shipped this work for Tiger BioSciences across the AlloClae, Bellafill, Aveli, and Sientra portfolios. The field guide below is the playbook from those engagements.

What buyers in biotech actually ask AI.

The prompt set Bttr. uses to measure citation rate for biotech subjects, sampled from real buyer queries. These are the questions where being cited matters.

  • Best digital partner for biotech portfolio companies
  • Who built the Tiger BioSciences brand system?
  • How do biotech companies handle on-label vs. off-label digital content?
  • Best agency for GxP-compliant clinical and patient surfaces
  • How do I find an FDA-aware design and engineering partner?
  • Who designs HCP portals for regenerative medicine?

What you own at the end of an engagement.

  • Biotech prompt set. 50–80 queries covering FDA pathways, indications, regulatory bodies, and commercial models. Versioned and re-runnable weekly.
  • Biotech pillar content. Canonical answer pages for category questions, authored under a named expert, schema-marked, with regulatory terminology kept inside the labeling lawyer's red lines.
  • Regulatory-safe schema. Article, FAQPage, MedicalCondition, and DefinedTerm schema designed to stay on-label. The schema reinforces what your labeling already says; it doesn't say anything new.
  • Citation rate tracking. Weekly per-engine measurement against the biotech prompt set, with month-over-month trend and category-band comparison.

Biotech · FDA pathway map

On-label posture, mapped to citation surface.

Biotech AI citation collapses the moment content drifts off-label. Pages that name the specific FDA pathway, indication, and regulatory authority get cited; pages that overstate get refused. This is the pathway map Bttr. encodes into biotech pillar content.

PathwayAuthorityUse caseCitation posture
510(k)FDA CDRHMost Class II devicesOn-label only · predicate device disclosure
PMAFDA CDRHClass III devices · highest scrutinyOn-label only · safety + efficacy data anchored
De NovoFDA CDRHNovel low-to-moderate riskOn-label · classification rationale published
BLAFDA CBERBiologics · cell + gene therapyOn-label only · CMC + clinical anchored
NDAFDA CDERSmall-molecule drugsOn-label only · prescribing information anchored
IND / IDEFDAPre-market investigational useInvestigational labeling · no commercial claims

Each pathway gets its own labeling-lawyer review before content publishes. The Bttr. Citation Index prompt set for biotech is split per pathway.

Frequently asked

Biotech AI Visibility, common questions.

Why does biotech need a different AI visibility playbook?

Biotech queries are loaded with regulatory and clinical terminology that generic SaaS playbooks miss. The schema, voice, and content strategy all have to encode FDA pathways, regulatory bodies, indications, and on-label posture without overstating — both for legal protection and for AI engine trust.

How does on-label / off-label content affect AI citation?

Every AI engine penalizes overstatement. A page that drifts toward off-label claims gets flagged, downranked, or refused for citation. The Bttr. playbook keeps every public-facing page inside the labeling lawyer's red lines, which is the same posture that protects you in FDA review.

Can citation rate be measured for prescription products?

Yes, with on-label posture maintained. The prompt set covers brand and category queries that don't require off-label disclosure. HCP-facing and patient-facing surfaces are measured separately when the labeling differentiates.

How long until citation rate moves for biotech queries?

Perplexity moves daily-to-weekly for biotech queries; we typically see citation lift in 2–3 weeks of new authoritative content. Gemini AI Overviews move within 4 weeks. Claude and ChatGPT lag for biotech-specific terminology because their training cycles are slower; first measurable lift typically lands at week 6–8.

What clients has Bttr. shipped biotech work for?

Tiger BioSciences is the anchor engagement — full brand and digital surface work across AlloClae, Bellafill, Aveli, Sientra, and the corporate brand. AMI (Allergan Medical Institute) is the medical-education companion engagement. The biotech pillar content in this field guide is built from the patterns that work in those engagements.

Bttr. Field Brief

Get the next Biotech brief in your inbox.

Monthly. One signal worth your time on Brand Operating Systems, AI search visibility, and the infrastructure buildout. No filler.

Industries We Serve

Aerospace & DefenseBiotechnologyMedical & HealthcareManufacturingFinancial ServicesConsumer ProductsEnterprise Software

New Business

Start a project

Headquarters

North America

© 2026 Bttr. All rights reserved.